Dashboard
Manage Tickers

MBRX Moleculin Biotech, Inc.

Nasdaq moleculin.com


$ 0.45 $ 0.02 (3.53 %)    

Friday, 31-Oct-2025 11:50:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 631.40 $ -2.60 (-0.41 %)
DIA $ 475.32 $ -0.61 (-0.13 %)
SPY $ 682.77 $ -2.20 (-0.32 %)
TLT $ 90.35 $ -0.21 (-0.23 %)
GLD $ 370.03 $ -0.48 (-0.13 %)
$ 0.4518
$ 0.43
$ 0.45 x 100
$ 0.45 x 99
$ 0.43 - $ 0.45
$ 0.25 - $ 3.65
43,693,889
na
13.68M
$ 1.66
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-24-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-19-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-16-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 02-21-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-28-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 04-03-2017 12-31-2016 10-K
36 11-21-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 06-16-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

moleculin-biotech-to-present-updates-on-its-ongoing-phase-3-miracle-clinical-trial-for-acute-myeloid-leukemia-at-14th-annual-acute-leukemia-meeting
Moleculin Biotech To Present Updates On It...
10/30/2025 12:42:11

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with...

moleculin-secures-australian-patent-for-preliposomal-annamycin-lyophilizate-with-enhanced-stability
Moleculin Secures Australian Patent For Pr...
10/29/2025 12:38:36

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with...

moleculin-biotech-enters-collaboration-with-atlantic-health-on-an-investigator-initiated-phase-1b2-study-to-evaluate-its-drug-candidate-annamycin-as-a-third-line-treatment-for-advanced-pancreatic-cancer
Moleculin Biotech Enters Collaboration Wit...
10/23/2025 12:05:14

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/22/2025 21:06:21

moleculin-biotech-secures-canadian-patent-titled-preparation-of-preliposomal-annamycin-lyophilizate
Moleculin Biotech Secures Canadian Patent ...
09/25/2025 12:40:12

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company wit...

moleculin-biotech-files-prospectus-for-resale-from-time-to-time-by-selling-stockholders-of-up-to-649m-shares-of-common-stock
Moleculin Biotech Files Prospectus For Res...
09/19/2025 21:21:15

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/18/2025 21:06:10

hc-wainwright--co-reiterates-buy-on-moleculin-biotech-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Mole...
09/10/2025 10:52:14

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

moleculin-biotech-announces-its-phase-2b3-miracle-trial-for-annarac-in-relapsed-or-refractory-acute-myeloid-leukemia-is-progressing-with-active-sites-and-ongoing-patient-recruitment-across-the-us-europe-and-the-middle-east
Moleculin Biotech Announces Its Phase 2B/3...
09/09/2025 12:48:45

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company wit...

moleculin-biotech-opens-spain-site-enrolls-first-rr-aml-patients-in-phase-2b3-miracle-trial-on-track-for-45-subjects-in-q4-2025
Moleculin Biotech Opens Spain Site, Enroll...
09/08/2025 12:41:48

Spain site opens with two R/R AML subjects enrolled; One treatedOn track to recruit 45 subjects in 4Q25 for initial data unblin...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 17:06:35

nasdaq-surges-100-points-dollar-general-earnings-beat-views
Nasdaq Surges 100 Points; Dollar General E...
08/28/2025 16:54:43

reported-earlier-moleculin-biotech-raises-6m-from-immediate-exercise-of-162m-warrants-at-037share-issues-649m-new-warrants-at-055share
Reported Earlier: Moleculin Biotech Raises...
08/28/2025 16:51:01

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with...

us-stocks-mixed-nvidia-posts-upbeat-earnings
US Stocks Mixed; Nvidia Posts Upbeat Earnings
08/28/2025 14:27:31

hc-wainwright--co-reiterates-buy-on-moleculin-biotech-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Mole...
08/27/2025 15:43:38

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

moleculin-biotech-completes-phase-1b2-clinical-trial-evaluating-annamycin-in-combination-with-cytarabine-for-acute-myeloid-leukemia
Moleculin Biotech Completes Phase 1B/2 Cli...
08/27/2025 12:48:14

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)Median OS of 2nd Line efficacy evaluable po...

moleculin-biotech-q2-eps-049-misses-042-estimate
Moleculin Biotech Q2 EPS $(0.49) Misses $(...
08/12/2025 21:57:24

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $...

moleculin-highlights-preclinical-data-for-annamycin-in-liver-cancers-reinforcing-late-stage-aml-development-and-broad-oncology-potential
Moleculin Highlights Preclinical Data For ...
08/06/2025 12:45:15

Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology in...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 21:07:05

moleculin-receives-notice-of-intent-to-grant-european-patent-titled-preparation-of-preliposomal-annamycin-lyophilizate
Moleculin Receives Notice Of Intent To Gra...
07/30/2025 12:36:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION